Email
Password
Remember meForgot password?
    Log in with Twitter
Press Release

Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market 2019: Worldwide Trend, Analysis by Top Leading Player and Forecast Till 2026

Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market 2019 Research by Business Opportunities, and Global Forecast to 2026 | Fortune Business Insights

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 06/28/2019 -- The Global Alpha-1 Antitrypsin Deficiency (Aatd) Augmentation Therapy Market has been supported by late FDA endorsement for Prolastin-C. According to a report published by Fortune Business Insights, titled "AATD Augmentation Therapy: Global Analysis, Insights and Forecast, 2019-2026", the market will be valued at US$ 1959.8 Mn by the end of 2026.

Sample PDF Brochure @ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/alpha-1-antitrypsin-deficiency-aatd-treatment-market-100189

Some of the major companies that are present in the Global Alpha-1 Antitrypsin Deficiency Treatment Market are;
- Grifols S.A.
- CSL Limited
- Baxter
- Kamada Ltd.
- Takeda Pharmaceutical Company Limited
- Abeona Therapeutics Inc., and other players.

The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market will exhibit a CAGR of 5.9% in the foreacast period. Fortune Business Insights expects that factors such as regulatory approvals and improvements in augmentation therapies will drive the market in this period.

Get Customization@ https://www.fortunebusinessinsights.com/enquiry/customization/alpha-1-antitrypsin-deficiency-aatd-treatment-market-100189

KEY PLAYERS COVERED
Some of the major companies that are present in the global alpha-1 antitrypsin deficiency treatment market are Grifols, CSL, Baxter, Kamada, Takeda, Abeona Therapeutics.

Grifols SA's AlfaCare Program Has Had a Positive Impact on the Global Market

In November 2018, Grifols Sa introduced AlfaCare, a therapy program aimed at providing training and counselling to Alpha-1 Antitrypsin Deficiency (Aatd) Augmentation Therapy Market patients diagnosed with AATD. Grifols stated that with AlfaCare, it aims to encourage new habits in patients and help them manage their disease properly. Research studies have proven that a huge percentage of people diagnosed with AATD were unaware about the symptoms, effects, and ways to treat the disorder. AlfaCare was launched to overcome all such shortcomings and improve the quality of patient care, thereby ascertaining reduced fatality rate of AATD. Thus, AlfaCare has transformed AATD augmentation therapies worldwide and is likely to boost the global AATD augmentation therapy market in the forecast period.

North America to Dominate the Global Market

The growth in global alpha-1 antitrypsin deficiency treatment market is being driven by the emerging guideline for the treatment and diagnosis of alpha-1 antitrypsin deficiency treatment, potential pipeline products and rising awareness of alpha-1 antitrypsin deficiency. Furthermore, the rising prevalence of alpha-1 antitrypsin deficiency is expected to boost the global alpha-1 antitrypsin deficiency treatment market in the forecast period.

Rising number of AATD cases in North America is fuelling the demand for AATD augmentation therapy in this region. This in turn has led to the growth of AATD augmentation therapy market in North America and is likely to favor growth of the market in this region through the forecast period. There have been significant improvements in AATD diagnostic techniques used in many parts of Asia Pacific. Furthermore, the emphasis on AATD by the government in Asia Pacific is likely to enable growth in the regional market in the forthcoming years. Despite North America's dominance, Asia Pacific will emerge as the fastest growing region in the forecast period.

New Biological Approval for Prolastin C to Enable Growth of Global Market

In September 2017, Grifols received biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C. The inclusion of this liquid may enable the launch of an additional alternative to the existing therapy. Clinical trials and proven efficacy have favored the approval for this product. With the latest addition to its product portfolio, Grifols will increase its stronghold in the global AATD augmentation therapy market.

As Grifols' products are used by a huge percentage of the global population, its new product approval will have a direct impact on the global market. Backed by successful therapies and efficient products, Grifols has accounted for the highest share in the global market. Recent product approvals have favoured the company and accounting to this, Grifols is likely to emrge dominant in the forecast period as well.

Know More:
https://www.fortunebusinessinsights.com/industry-reports/alpha-1-antitrypsin-deficiency-aatd-treatment-market-100189

About Us:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

For more information on this press release visit: http://www.sbwire.com/press-releases/alpha-1-antitrypsin-deficiency-aatd-augmentation-therapy-market-2019-worldwide-trend-analysis-by-top-leading-player-and-forecast-till-2026-1239754.htm

Media Relations Contact

Ashwin Arora
Sales Manager
Fortune Business Insights Pvt. Ltd.
Telephone: 1-424-253-0390
Email: Click to Email Ashwin Arora
Web: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/alpha-1-antitrypsin-deficiency-aatd-treatment-market-100189

Latest News
Top News